Related Experiment Video
Updated: Apr 23, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
A context-based matched molecular pair analysis identifies structural transformations that reduce CYP1A2 inhibition
Janvi A Raut1, Vaibhav A Dixit1
1Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER Guwahati), Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Govt. of India Sila Katamur (Halugurisuk), P.O.: Changsari, Dist: Kamrup 781101 Guwahati Assam India vaibhavadixit@gmail.com vaibhav@niperguwahati.in.
Abstract:
Cytochrome P450 1A2 (CYP1A2) metabolizes ∼10-15% of FDA-approved drugs. Available quantitative structure-activity relationship (QSAR) and machine learning methods offer little design insights to reduce CYP1A2 inhibition. We performed matched molecular pair analysis (MMPA) on the CYP1A2 inhibition dataset (ChEMBL3356) and identified key structural transformations. A chemical context-based analysis was performed using Kramer's method to tackle the limitations of the global MMPA. The global MMPA agreed with earlier QSAR studies (influence of H to F, Me, OMe, and OH transformations). Our results show that the effect of these transformations depends on the local chemical environment. The H to Me transformation reduced the inhibition in three pharmacologically important scaffolds (e.g., indanylpyridine). Structure-based analysis (docking) showed that the interaction of the heteroatoms with Heme-Fe is influenced by useful transformations. Overall, this work presents the first context-based analysis of the CYP1A2 dataset and offers novel medicinal chemistry insights useful for lead optimization.
More Related Videos
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
[3,3] Sigmatropic Rearrangement of 1,5-Dienes: Cope Rearrangement
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

